Alkem Laboratories share price
NSE: ALKEMBSE: 539523Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹5,013.50.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹59,149 Cr164th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 14 Aug 2026
- 27.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 28 May 2026
- 4.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.07%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 Aug 2026
- 16.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- 16.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 28 May 2026
- 0.11
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 54,98251.0% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 14 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹3,740 Crup 3.80%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹521 Crup 107.47%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 13.9%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 13 Nov | Dec 2024Filed 7 Feb | Mar 2025Filed 27 Jun | Jun 2025Filed 12 Aug | Sep 2025Filed 13 Nov | Dec 2025Filed 13 Feb | Mar 2026Filed 28 May | Jun 2026Filed 14 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 | 3,737 | 3,603 | 3,740 |
| Net profit | 702 | 641 | 322 | 668 | 779 | 653 | 251 | 521 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 20.6% | 19.0% | 10.3% | 19.8% | 19.5% | 17.5% | 7.0% | 13.9% |
Business segments
In the year to Mar 2026 the company reports one business segment, The Company is exclusively engaged in pharmaceutical business, which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
At or below today's level on 38% of 2,212 trading days since Nov 2016.
At or below today's level on 17% of 1,975 trading days since Nov 2018.
At or below today's level on 18% of 1,975 trading days since Nov 2018.
At or below today's level on 81% of 2,480 trading days over the last 10 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +9.5% | +6.3% | +2.1% | 1.0% |
| 3 years | +16.9% | +32.7% | −12.6% | 0.9% |
| 5 years | +14.9% | +7.7% | +5.7% | 1.0% |
Mutual funds holding it
201 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 100 of the 130 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 2 more funds filed their first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 3
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 6
- AddedAdded. Funds that held more shares than at the end of the month before.
- 103
- CutCut. Funds that held fewer shares than at the end of the month before.
- 27
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 60
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 11
| Fund | |||
|---|---|---|---|
 HDFC Mid Cap FundHDFC Mutual Fund | 33,88,530 | 1.72% | ₹1,749.7 Cr |
 ICICI Prudential Multi Asset Allocation FundICICI Prudential Mutual Fund | 15,49,513 | 0.95% | ₹800.1 Cr |
 SBI Large & Midcap FundSBI Mutual Fund | 14,76,712 | 1.88% | ₹762.5 Cr |
 Nippon India Growth Mid Cap FundNippon India Mutual Fund | 12,30,397 | 1.27% | ₹635.3 Cr |
 Axis Midcap FundAxis Mutual Fund | 8,92,035 | 1.37% | ₹460.6 Cr |
 DSP Large & Mid Cap FundDSP Mutual Fund | 6,55,901 | 1.96% | ₹338.7 Cr |
| DSP Midcap FundDSP Mutual Fund | 6,45,036 | 1.71% | ₹333.1 Cr |
| ICICI Prudential Healthcare FundICICI Prudential Mutual Fund | 6,39,791 | 4.81% | ₹330.4 Cr |
 Kotak Arbitrage FundKotak Mahindra Mutual Fund | 5,64,500 | 0.39% | ₹291.5 Cr |
| HDFC Balanced Advantage FundHDFC Mutual Fund | 5,59,771 | 0.28% | ₹289.0 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Alkem Laboratories in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Mankind PharmaMANKIND | 91,390 | 44.6 | 5.6 | 25.4 | +13.8% | +8.2% | 13.4% | 12.8% | 0.00% |
 Aurobindo PharmaAUROPHARMA | 90,432 | 24.4 | 2.4 | 12.5 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
 LupinLUPIN | 88,207 | 16.0 | 3.9 | 9.3 | +28.2% | +49.5% | 27.9% | 28.2% | 0.93% |
 Glenmark PharmaceuticalsGLENMARK | 61,147 | 34.0 | 5.8 | 12.5 | +32.9% | +138.4% | 18.6% | 39.8% | 0.12% |
 Abbott IndiaABBOTINDIA | 53,187 | 32.9 | 11.1 | 25.9 | +6.3% | +11.2% | 35.9% | 39.6% | 2.62% |
 BioconBIOCON | 52,721 | 106.4 | 1.5 | 18.2 | +9.8% | +28.6% | 1.8% | 2.9% | 0.15% |
 IPCA LaboratoriesIPCALAB | 49,556 | 37.8 | 6.1 | 22.3 | +10.6% | +68.2% | 17.4% | 17.6% | 0.31% |
 Gland PharmaGLAND | 46,645 | 41.3 | 4.5 | 24.9 | +17.6% | +46.5% | 11.6% | 12.4% | 0.71% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 7 Aug 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹10.00 |
| 20 Feb 2026 | Interim | ₹43.00 |
| 8 Aug 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹8.00 |
| 14 Feb 2025 | Interim | ₹37.00 |
| 9 Aug 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹5.00 |
| 16 Feb 2024 | Interim | ₹35.00 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
24 Sep · Management
23 Sep · Analysts
Alkem Laboratories share price by year
Each calendar year to 2025.Alkem Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 5,506.50 | −2.3% | 5,773.00 | 4,563.70 |
| 2024 | 5,633.90 | +8.3% | 6,366.25 | 4,616.35 |
| 2023 | 5,202.60 | +73.1% | 5,202.60 | 3,000.70 |
| 2022 | 3,004.70 | −17.1% | 3,736.55 | 2,902.75 |
| 2021 | 3,624.05 | +23.8% | 4,003.10 | 2,574.80 |
| 2020 | 2,926.20 | +45.3% | 2,981.95 | 2,082.85 |
| 2019 | 2,013.90 | +3.3% | 2,117.05 | 1,669.00 |
| 2018 | 1,949.20 | −11.5% | 2,323.60 | 1,745.45 |
| 2017 | 2,201.90 | +35.2% | 2,211.30 | 1,622.25 |
| 2016 | 1,628.65 | +9.7% | 1,844.85 | 1,186.45 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 4,975.50 | 5,019.50 | 4,877.00 | 4,947.00 | 4,928.84 | 54,982 | 51.0% |
| 22 Oct 2026 | 4,982.00 | 5,015.00 | 4,811.00 | 5,013.50 | 4,955.69 | 49,335 | 33.6% |
| 21 Oct 2026 | 4,979.00 | 5,050.50 | 4,891.50 | 5,015.00 | 4,947.54 | 2,79,107 | 70.5% |
| 19 Oct 2026 | 5,042.50 | 5,099.50 | 4,975.50 | 5,004.00 | 5,025.21 | 95,218 | 59.8% |
| 16 Oct 2026 | 5,138.50 | 5,147.00 | 5,042.00 | 5,050.00 | 5,065.25 | 1,60,798 | 74.0% |
| 15 Oct 2026 | 5,210.00 | 5,249.00 | 5,120.50 | 5,120.50 | 5,171.49 | 59,913 | 54.8% |
| 14 Oct 2026 | 5,259.00 | 5,270.50 | 5,171.00 | 5,201.00 | 5,205.82 | 79,840 | 62.9% |
| 13 Oct 2026 | 5,206.00 | 5,288.50 | 5,172.00 | 5,250.00 | 5,238.21 | 1,03,084 | 57.7% |
| 12 Oct 2026 | 5,256.50 | 5,300.50 | 5,201.00 | 5,205.00 | 5,255.34 | 1,79,595 | 80.4% |
| 9 Oct 2026 | 5,252.00 | 5,299.00 | 5,225.00 | 5,279.00 | 5,263.48 | 96,074 | 56.0% |
About Alkem Laboratories
Alkem Laboratories is a diversified healthcare company headquartered in Mumbai. Its core business is branded and trade generic prescription medicines sold in India. It also makes active pharmaceutical ingredients (APIs, the raw chemicals that give a medicine its effect), sells consumer health products under the ActivLife name, and runs an international business.
The business is organised into Domestic Pharma, Branded and Trade Generics, OTx and APIs, ActivLife and Alkem Activa, International Business, Biotech, which covers biosimilars and contract biologics manufacturing, and MedTech. Biosimilar work is carried out through Enzene Biosciences. The MedTech business is centred on orthopaedics and cardiovascular devices. The trade generics business sits in a wholly owned subsidiary, Alkem Wellness.
In India, Alkem has eighteen manufacturing units across Sikkim, Baddi, Daman, Mandva, Ankleshwar and Pune, and it also manufactures in the United States. Worldwide it has 20 manufacturing plants, five of them approved by the US drug regulator, and three research centres. Its portfolio in India covers more than 800 brands. It serves more than forty countries, directly or through partnerships, with a presence across the United States, Europe, Australia, Latin America, the CIS region, the Middle East, Africa and Southeast Asia.
Alkem was founded in 1973 by the late Shri Samprada Singh, together with Basudeo N. Singh, who is its Co-Founder and Executive Chairman. It entered MedTech through a licensing agreement with Advita Ortho and has completed the acquisitions of Adroit and Bombay Ortho.
- Legal name
- Alkem Laboratories Limited
- NSE symbol
- ALKEM
- BSE code
- 539523
- ISIN
- INE540L01014
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Dec 2015
- Face value
- ₹2
- CIN
- L00305MH1973PLC174201
- Corporate identity number, the registrar of companies' code for it